contact us

DiagnosTear is a leading
ophthalmic company developing
and commercializing disruptive
diagnostic solutions for better
management of eye diseases

DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases

about us

DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. DiagnosTear’s TeaRx™ technology is a diagnostic platform intended for Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid. The first CE-IVD approved test based on the TeaRx™ platform is intended for the identification and monitoring of Dry Eye Syndrome (TeaRx™ DES). DiagnosTear’s pipeline tests include TeaRx™ Red Eye; The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis and Allergic conjunctivitis.

our products

TeaRx™ Dry Eye

The first CE-IVD approved test based on the TeaRx™ platform is intended for the identification and monitoring of Dry Eye Syndrome (TeaRx™ DES).

read more

TeaRx™ Tear Collector

DiagnosTear’s proprietary microfluidic tear collector is an integral part of the TeaRxTM Technology.

read more

TeaRx™ Red Eye

The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis and Allergic conjunctivitis.

read more

Annual Incidence

Dry eye (worldwide)
0 M
Ocular Adenovirus (US)
0 M
Ocular Herpes (worldwide)
0 M
Ocular Allergy (US)
0 M

– our vision

DiagnosTear aims to become the global leader in rapid, TEAR-based ophthalmologic diagnostics.

DiagnosTear (CSE:DTR) Now Public

symbol: DTR

0.25

Last Price:

(8.7%)

0.02

Change:

0.25

Day High:

500

Volume:

Last updated 13:30 ET

news

February 19, 2025

Prof. Sayan Basu to Present Pivotal Results of Largest Dry Eye Syndrome Clinical Study with DiagnosTear’s TeaRxTM Product at ARVO 2025

DiagnosTear is Pleased to announce that an abstract titled “A Novel Multi-Parameter Point-of-Care Tear Film Test for Diagnosis of Dry Eye Syndrome, Severe Meibomian Gland Dysfunction, and Responsiveness to Therapy” has been accepted for oral presentation
read more
February 4, 2025

DiagnosTear Advances Production for First 100,000 TeaRxTM Red Eye Diagnostic Devices

DiagnosTear is pleased to announce the completion of the plastic injection mold for the production of its first 100,000 TeaRxTM Red Eye diagnostic devices. This achievement marks a milestone in the Company’s operational and commercial readiness, setting the stage for large-scale manufacturing of the innovative TeaRxTM Red Eye product.
read more
January 14, 2025

Don’t Let Dry Eye Derail Your Vision

January 14, 2025 TeaRxTM is the diagnostic tool of choice for assessment of DES before and after cataract or refractive surgeries, as it may offer critical information addressing the recently-published AAO guidelines
read more

fast nav

contact us

Phone: 073-2753400
Email: [email protected]

Linkedin X-twitter

Prof. Leonard Bielory

  • Professor of Medicine, Allergy, Immunology, and Ophthalmology
  • Top expert in the diagnosis and treatment of allergic conjunctivitis and ocular allergies
  • Ex – Director of the Allergy and Immunology Section at Rutgers University
  • Has authored over 200 peer-reviewed publications

Brian Smith

  • General Manager, eye Health at Quidel-Ortho
  • Ex- Surgical Account Consultant Surgical Account Consultant and area manager at Allergan
  • Ex – Cataract Account Manager at Alcon
  • Ex – Teaching Institute Manager/Refractive Implant Specialist at Abbott

Dr. Ron Neumann

  • CMO of BioLight
  • Expert ophthalmologist, specializing in inflammatory eye diseases
  • Senior consultant to Maccabi HMO
  • Former Global Medical Director for innovative Products – TEVA
  • Co chairman – ISOPT
  • Founder – FOIS

Prof. David Zadok

Director

  • Director of Ophthalmology at Shaare Zedek MC, Jerusalem. 
  • Former Chairperson OIS
  • Former Head of the Israel Cornea Society 
  • Fellowship in Corneal Diseases UCSD, San Diego
  • Co-authored over 70 scientific publications, 2 book chapters
  • Member of AAO, Asia Cornea Society and Israeli Society of Vision and Eye Research

John Sinclair

Director

Mr. Sinclair is a Canadian CPA with extensive experience in the field of finance, accounting and the audit of public companies. With a career spanning several decades, he has served as Senior Partner with various audit firms including Smith, Nixon LLP, Collins Barrow Toronto LLP and Baker Tilly WM LLP, including as Managing Partner of Baker Tilly WM LLP’s Toronto office. During these tenures, Sinclair played a pivotal role in initiating and driving growth, managing complex projects, and providing financial advisory services to clients around the world. Mr. Sinclair is currently a director of Lifeist Wellness Inc. (“Lifeist”), a company listed on the TSX Venture Exchange, where he also serves as the chair of the Lifeist audit committee. Mr. Sinclair graduated from the University of Toronto with a Bachelor of Arts, Commerce and Economics, in April 1983.

Igal Kohn

Director

Igal Kohn is currently, and has been since January 2017, the CEO of Elcam. Mr. Kohn has been with Elcam for over 25 years, starting in January 1998 as the CFO. Mr. Kohn holds an Israeli CPA certification. As the CFO of Elcam, Mr. Kohn was responsible for overseeing all mergers and acquisitions activities, managing the Elcam’s subsidiaries and handling all financial and legal matters. Mr. Kohn’s extensive experience in financial management and strategic operations positioned him to lead Elcam as CEO.

Karin Gurevitz

Director

Karin Gurevitz has served as BioLight Vice President, BioLight Group General Counsel and Company Secretary since 2015. Ms. Gurevitz is a veteran legal advisor with 25 years of experience in legal and compliance management in global public and private companies in various fields. Ms. Gurevitz holds an LL.B. and an MBA from Tel Aviv University, Israel and is a member of the Israel Bar Association.

Julia Reznick Zilberman

Director

Julia Reznick Zilberman has been serving as VP of Business Development at Psifas (National Initiative for Precision Medicine) since May 2024. Before joining Psifas, Ms. Reznick Zilberman led strategic initiatives 96 at a company developing AI solutions for drug development (January 2023 to February 2024) and served as VP of Finance (CFO) and Business Development at an innovative ophthalmology startup (January 2018 to January 2023), which successfully completed several funding rounds. Prior to that, Ms. Reznick worked for 18 years at Teva Pharmaceutical Industries, where she held various senior finance and commercial roles, including managing financial strategy and operations. Ms. Reznick Zilberman also consults for startup companies, providing her expertise in business development and financial strategy. Ms. Reznick Zilberman holds an MBA in Finance and Information Systems, as well as a bachelor’s degree in Economics and Management, both from Tel Aviv University.

Yifftach Biel

Chief Financial Officer

  • CFO – BioLight (TASE:BOLT)
  • Ex BioLight corporate controller
  • Ex Delek Global Real Estate (AIM:DGRE)
  • Certified CPA

Dr. Amos Sommer

VP Technology

  • Almost 3 decades experience in IVD R&D
  • World expert in developing lateral-flow rapid tests
  • Developed the HIV rapid test line for Alere (now Abbott)
  • Developed the TeaRx™ core platform and DES test

Dr. Shimon Gross

Chief Executive Officer

  • >20 years experience in IVD
  • Ex VP Genomics division– AID Genomics 
  • Ex VP Sales & Marketing  – Savyon Diagnostics
  • >25 peer-reviewed publications and patents

Yaacov Michlin

Chairman of the Board

Yaacov Michlin has served as CEO of Biolight since April 2020. Before joining Biolight, Mr. Michlin managed a medical device company selling mainly in U.S. and led such company’s initial public offering on the NASDAQ. Mr. Michlin currently serves on various boards of directors in the portfolio of Biolight and is leading the life sciences activities in IATI (umbrella organization of the Israeli high-tech sector). Mr. Michlin is also the chairman of MIXIII Health Tech IL, a major conference in Israel. Mr. Michlin has an MBA from the Technion, cum laude, LLM and LLB and BSC in Economics, cum laude, Bar Ilan University.